Vistagen shares surge 11.26% premarket after appointing Nick Tressler as CFO.

Vistagen Therapeutics (VTGN) surged 11.26% in premarket trading following the announcement that Nick B. Tressler was appointed as Chief Financial Officer and Treasurer on December 1, 2025. Tressler succeeds Shawn K. Singh in an interim role and brings expertise in biotech finance, potentially signaling improved capital management and strategic direction. This leadership change, coupled with prior updates on phase 3 trial progress for social anxiety treatment and recent collaborations, reinforced investor confidence in the company’s operational and clinical development trajectory. While older news about trial data and quarterly results contributed to prior gains, the immediate premarket rally aligns with the perceived strength of Tressler’s appointment in stabilizing the firm’s financial outlook.